Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...

Immune cell boost could enable lasting vaccine protection

A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...

Genes influence when babies start walking

Genetics accounts for about a quarter of the differences in when children take their first steps,...

Content from other channels on our network

Nearing the peak: NSW elective surgery waiting list figures

Investment in new Bankstown Hospital reaches record $2 billion

Community pharmacy invites 'pop ins' this Men's Health Week

APNA is searching for its next CEO

Monash IVF extends scope of review after second embryo incident

Demand surges for household batteries

Aussie execs to report emissions regardless of politics

Conspiracy mentality drives misinformation about EVs

Underwater noise modelling program to protect marine life

Mitigating the decline of FCAS prices

AI-enabled configuration translation

Software-defined automation: powering the next generation of process industries

UTS to open Australia's largest spacecraft manufacturing facility

Navigating SIF logic solver selection: Why the Moore Industries SLA stands out

Heat exchangers expand ginger beer production in Bundaberg